Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP policies and guidelines news

Show

From To
PrEP policies and guidelines
Indonesia commits to piloting PrEP

Indonesia has decided to pilot pre-exposure prophylaxis (PrEP) in four cities with high levels of HIV prevalence.

Published
21 July 2019
From
UNAIDS
PrEP
Market for HIV Prevention Drugs May More Than Double, Citi Says

An experimental drug from Merck & Co may lead the way in the U.S. market, Citi said. Baum estimates MK-8591 may reach sales of $7 billion in HIV. Of that total, $3.5 billion may come from pre-exposure prophylaxis, or PrEP, as the preventative treatments are called.

Published
21 July 2019
From
Bloomberg
Pharmaceutical industry
Are 2 million bottles of PrEP an empty gesture?

Gilead should either commit to providing all the doses of PrEP required for everyone who would benefit or open the market up to a range of generic manufacturers.

Published
15 July 2019
From
The Lancet HIV
PrEP policies and guidelines
In New York City, PrEP on Demand Is Now on the Menu for Men Who Have Sex With Men

For a long time, the most common way to describe pre-exposure prophylaxis (PrEP) was that it is a daily pill taken to prevent acquiring HIV. But now, New York City is tackling what might be a barrier to PrEP uptake with its new on-demand PrEP initiative.

Published
11 July 2019
From
The Body Pro
PrEP policies and guidelines
Insurance Will Soon Cover HIV Prevention, But Many People Who Need it Still Won't Have Access

When Corey Walsh began using the drug Truvada, the pills were free but the quarterly lab tests and doctors' visits cost almost $400.

Published
11 July 2019
From
Vice
PrEP programmes and uptake
Same-day PrEP initiation a favorable option for patients at risk for HIV

Same-day initiation of pre-exposure prophylaxis, or PrEP, for HIV prevention was found to be safe, feasible and well-received among patients at a walk-in STD clinic, according to a recently published study. During the study, which was conducted at a clinic in Denver, a high proportion of the participants were linked to ongoing PrEP care, researchers reported.

Published
10 July 2019
From
Healio
PrEP policies and guidelines
NHS England recommends uncapped PrEP trial access

NHS England have announced five steps towards better access to the HIV prevention drug PrEP, including recommending removing the capped number of places on the ongoing IMPACT Trial. This follows a meeting yesterday between Simon Stevens, chief executive of NHS England, NAT (National AIDS Trust), Terrence Higgins Trust, and PrEPster.

Published
08 July 2019
From
National Health Executive
Pharmaceutical industry
What Does PrEP Cost Outside the United States?

For the past several years, doctors in the United States have watched enviously as other countries have approved generic versions of PrEP made by Mylan, Teva, and other generic drug companies. These cheaper generics have made it easier for governments to support large PrEP scale-up programs.

Published
04 July 2019
From
The Body
Pharmaceutical industry
HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?

On Tuesday, the Department of Health and Human Services was awarded a new patent that broadly covers medicines derived from tenofovir and used to prevent HIV.

Published
03 July 2019
From
STAT
PrEP policies and guidelines
FDA Eliminates REMS for HIV Drug Truvada and its Generics

The US Food and Drug Administration (FDA) announced late Monday that it would eliminate the risk evaluation and mitigation strategy (REMS) for Gilead's Truvada (emtricitabine/tenofovir disoproxil fumarate) and its four approved generics, which reduce the risk of sexually acquired HIV.

Published
02 July 2019
From
Regulatory Focus
← First12345...11Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.